


Appendix A

Claim Amendments

1. (Currently amended) Compounds A compound of formula 1,



in which

R1 is 1-4C-alkyl,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy,
3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is com-
pletely or predominantly substituted by fluorine,

R3 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy,
3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is
completely or predominantly substituted by fluorine,

or in which

R2 and R3 together are a 1-2C-alkylenedioxy group,

R4 is hydrogen, halogen, nitro, 1-4C-alkyl,
trifluoromethyl or 1-4C-alkoxy,

R5 is hydrogen, 1-8C-alkyl, 3-7C-cycloalkyl or phenyl-1-
4C-alkyl,

R6 is 1-4C-alkyl, phenyl-1-4C-alkyl, or Aryl-1-4C-alkyl,
in which

Aryl is R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkoxy, trifluoromethyl or cyano,

R62 is 1-4C-alkoxy,

and in which either

R7 is 1-4C-alkyl, and

n is 1 or 2,

or

R7 is hydrogen, and

n is 1, 2 or 3,

or a salt, N-oxide or salt of an N-oxide thereof

~~the salts, the N-oxides of these compounds and the salts of~~
~~the latter.~~

2. (Currently amended) Compounds A compound of formula 1
according to claim 1 in which

R1 is 1-4C-alkyl,

R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy,

3-5C-cycloalkylmethoxy, or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R3 is 1-2C-alkoxy, 3-5C-cycloalkoxy,

3-5C-cycloalkylmethoxy, or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R4 is hydrogen, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R5 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or phenyl-1-4C-alkyl,

R6 is 1-4C-alkyl, phenyl-1-4C-alkyl, or Aryl-1-4C-alkyl,
in which

Aryl is R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkoxy, trifluoromethyl or cyano,

R62 is 1-4C-alkoxy,

R7 is hydrogen or 1-4C-alkyl,

n is 1 or 2,

or a salt, N-oxide or salt of an N-oxide thereof

~~the salts, the N-oxides of these compounds and the salts of the latter.~~

3. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is methyl,

R2 is 1-2C-alkoxy,

R3 is 1-2C-alkoxy,

R4 is hydrogen,

R5 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or phenyl-1-4C-alkyl,

R6 is 1-4C-alkyl, phenyl-1-4C-alkyl, or Aryl-1-4C-alkyl,

in which

Aryl is 1-4C-alkoxy-substituted phenyl, trifluoromethyl-substituted phenyl, cyano-substituted phenyl, or R61- and R62-substituted phenyl, in which

R61 is 1-4C-alkoxy,

R62 is 1-4C-alkoxy,

and in which either

R7 is hydrogen or 1-4C-alkyl,

n is 1 or 2,

or a salt, N-oxide or salt of an N-oxide thereof

~~the salts, the N-oxides of these compounds and the salts of the latter.~~

4. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is methyl,

R2 is ethoxy,

R3 is methoxy,

R4 is hydrogen,

R5 is hydrogen, methyl, ethyl, propyl, isopropyl,
cyclohexyl or benzyl,

R6 is methyl, ethyl, isopropyl, butyl, benzyl, 3-
phenylpropyl, or Aryl-methyl, in which

Arylis 4-methoxyphenyl, 4-trifluoromethylphenyl, 4-
cyanophenyl or 3,5-dimethoxyphenyl,

and in which either

R7 is hydrogen or methyl, and

n is 1 or 2,

or

R7 is ethyl or isobutyl, and

n is 1,

or a salt, N-oxide or salt of an N-oxide thereof



~~the salts, the N-oxides of these compounds and the salts of~~

~~the latter.~~

5. (Currently amended) A compound of formula 1 according
to claim 1 any of the preceding claims, in which the
hydrogen atoms in positions 4a and 10b are in the cis

position relative to one another, or a salt, N-oxide or salt of an N-oxide thereof.

6. (Currently amended) A compound of formula 1 according to claim 1, any of the preceding claims which have with respect to the chiral centers, the configuration shown in formulae (1*) or (1**):



or a salt, N-oxide or salt of an N-oxide thereof.

7. (Canceled)

8. (Currently amended) A pharmaceutical composition comprising one or more compounds of formula 1 as claimed in claim 1, or a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof, together with a pharmaceutically acceptable auxiliary and/or excipient customary pharmaceutical auxiliaries and/or excipients.
9. (Canceled)
10. (Currently amended) A method for treating an illness treatable by the administration of a PDE3/4 inhibitor in a patient comprising administering to said patient in need thereof a therapeutically effective amount of a compound of formula 1 as claimed in claim 1, or a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof.
11. (Currently amended) A method for treating an airway disorder disorders and/or dermatoses in a patient comprising administering to said patient a therapeutically effective amount of a compound of

formula 1 as claimed in claim 1, or a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof.